



IFW

PATENT  
Attorney Docket No. 056291-5172

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Laurent F. A. HENNEQUIN</b>	)	Confirmation No. 7795
	)	
Application No.: <b>10/502,538</b>	)	Group Art Unit: <b>1624</b>
	)	
Filed: <b>July 28, 2004</b>	)	Examiner: <b>Truong</b>
	)	
For: <b>QUINAZOLINE COMPOUNDS</b>	)	

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

January 9, 2006

Sir:

**RESUBMISSION OF INFORMATION DISCLOSURE STATEMENT FILED  
SEPTEMBER 30, 2005 WITH MISSING FORM PTO-1449**

Submitted herewith is a copy of the Information Disclosure Statement filed in this application on September 30, 2005. This copy has been taken from the PTO PAIR website, and the undersigned has just become aware from the note on the bottom of the first page thereof that the PTO did not receive the PTO-1449 that accompanied (or was supposed to accompany) the September 30, 2005 Information Disclosure Statement. Accordingly, also submitted herewith is the form PTO-1449 that was prepared for filing on September 30, 2005.

It appears from the PAIR website that a copy of each non-US Patent document cited in this form PTO-1449 was submitted and received by the PTO. Therefore, further copies of the documents are not being submitted herewith. However, if the Examiner finds that any cited document is missing, it is respectfully requested that the Examiner telephone the undersigned, and a copy will forthwith be provided.

It is respectfully requested that the Examiner consider each of the cited documents and acknowledge consideration of the same by returning an initialed copy of this form PTO-1449 to the undersigned.


**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due

under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

**CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,  
Morgan Lewis & Bockius LLP



Date: January 9, 2006  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001



PATENT  
Attorney Docket No. 056291-5172

1624  
\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Laurent F. A. HENNEQUIN**

Application No.: **10/502,538**

Filed: **July 28, 2004**

For: **QUINAZOLINE COMPOUNDS**

) Confirmation No. 7795  
)  
)  
) Group Art Unit: 1624  
)  
)  
) Examiner: Truong  
)

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

September 30, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. This Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

10/03/2005 HGBRENI 00000018 500310 10502534  
01 FC:1806 180.00 DA

1-WA/2459687.1


The PTO did not receive the following  
list item(s) PTO-1449

BEST AVAILABLE COPY

It is believed a fee of \$180.00 is due for this Information Disclosure Statement. Kindly charge this fee, if due, and any other fees and/or credits, to Deposit Account No. 50-0310.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,  
Morgan Lewis & Bockius LLP



Date: September 30, 2005  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

BEST AVAILABLE COPY

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. <b>056291-5172</b>		Application No. <b>10/502,538</b>	
PTO Form 1449				Applicants: <b>Laurent F. A. HENNEQUIN</b>			
Filing Date: <b>July 28, 2004</b>				Group Art Unit: <b>1624</b>			
<b>U.S. PATENT DOCUMENTS</b>							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1.	US 2002/0177601	Himmelsbach et al.			August 23, 2001	
	2.	US 5,409,930	Spada et al.			May 6, 1992	
	3.	US 5,411,963	Dreilcorn et al.			July 19, 1993	
	4.	US 5,480,883	Spada et al.			December 10, 1993	
	5.	US 5,646,153	Spada et al.			May 11, 1995	
	6.	US 5,710,158	Myers et al.			April 19, 1994	
	7.	US 5,714,493	Myers et al.			June 4, 1996	
	8.	US 5,721,237	Myers et al.			June 6, 1995	
	9.	US 5,736,534	Arnold et al.			January 27, 1995	
	10.	US 6,046,206	Pamukcu et al.			April 30, 1997	
	11.	US 6,057,320	Spada et al.			June 25, 1997	
	12.	US 6,153,617	Bridges			July 29, 1998	
	13.	US 6,162,804	Bilodeau et al.			March 11, 1999	
	14.	US 6,225,318	Sobolov-Jaynes et al.			November 26, 1999	
	15.	US 6,531,491	Kania et al.			October 25, 2001	
	16.	US 6,645,969	Myers et al.			May 18, 1995	
	17.	US Re. 36,256	Spada et al.			December 10, 1997	
<b>FOREIGN PATENT DOCUMENTS</b>							
	Document No.	Date	Country	Class	Sub-Class	Translation	
	18.	DE 19614718	Germany				
	19.	EP 0326330	Europe				
	20.	EP 0602851	Europe				
	21.	EP 0837063	Europe				
	22.	EP 1029853	Europe				
	23.	GB 2345486	Great Britain				
	24.	WO 87/04321	WIPO				
	25.	WO 92/20642	WIPO				
	26.	WO 95/15758	WIPO				
	27.	WO 95/19169	WIPO				
	28.	WO 95/23141	WIPO				
	29.	WO 95/24190	WIPO				
	30.	WO 96/29301	WIPO				
	31.	WO 96/39145	WIPO				
	32.	WO 97/03069	WIPO				
	33.	WO 97/17329	WIPO				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Attorney Docket No. <b>056291-5172</b>	Application No. <b>10/502,538</b>				
PTO Form 1449		Applicants: <b>Laurent F. A. HENNEQUIN</b>					
Filing Date: <b>July 28, 2004</b>		Group Art Unit: <b>1624</b>					
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	Class	Sub-Class	Translation
	34.	WO 97/30034	August 21, 1997	WIPO			
	35.	WO 97/42187	November 13, 1997	WIPO			
	36.	WO 98/02434	January 22, 1998	WIPO			
	37.	WO 98/54093	December 3, 1998	WIPO			
	38.	WO 99/06396	February 11, 1999	WIPO			
	39.	WO 99/10349	March 4, 1999	WIPO			
	40.	WO 99/21859	May 6, 1999	WIPO			
	41.	WO 99/35132	July 15, 1999	WIPO			
	42.	WO 99/35146	July 15, 1999	WIPO			
	43.	WO 00/06554	February 10, 2000	WIPO			
	44.	WO 00/12497	March 9, 2000	WIPO			
	45.	WO 00/44728	August 3, 2000	WIPO			
	46.	WO 00/47212	August 17, 2000	WIPO			
	47.	WO 00/55141	September 21, 2000	WIPO			
	48.	WO 01/02369	January 11, 2001	WIPO			
	49.	WO 01/29025	April 26, 2001	WIPO			
	50.	WO 01/74360	October 11, 2001	WIPO			
	51.	WO 03/20699	March 13, 2003	WIPO			
	52.	WO 03/37252	May 8, 2003	WIPO			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	53.	Gazit et al., Tyrophostins IV-Highly Potent Inhibitors...Relationship Study of 4-Anilidoquinazolines, Bioorganic & Medicinal Chemistry, Vol. 4. No. 8, 1996, pp. 1203-1207					
	54.	Gibson et al., Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines, Bioorganic & Medicinal Chemistry, Vol. 7, No. 21, 1997, 2723-2728					
	55.	Hara et al., On the Amination of Azaheterocycles. A New Procedure for the Introduction of an Amino Group (1), J. Heterocyclic Chem. Vol. 19, 1982, pp. 1285-1287					
	56.	Karminski et al., The Synthesis of Some Quinazoline Derivatives and Their Biological Properties; J. Environ. Sci. Health, Vol B18, 1983, pp. 599-610					
	57.	Sinyak, et al., Synthesis and Biological Properties of Derivatives of 4-Heterylmercaptoquinazoline, Zaporozh'e Medical Institute pp. 103-106, translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, Feb. 1986, 168-171, original article submitted 12/29/84					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							